AβO levels measured by amplification-MDS protocol were higher in patients with AD compared to control individuals, and correlated well with conventional AD biomarkers, such as Aβ42, P-tau and T-tau levels in CSF and PiB-SUVR imaging value [75]. The gene discussed is MAPT; the disease is Alzheimer disease.